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Introduction
In 2001 the European Union adopted the EU Clinical Trials
Directive (2001/20/EC) as a framework for good man-
agement in trials of medicines [4]. Many concerns were
expressed that this Directive would impede and inhibit
publicly funded clinical trials [2, 7, 14].
The question is if the concerns regarding the Clinical
Trials Directive were legitimate. In other words, has the
Directive really made it practically impossible for a group
of surgeons to initiate, organize and conduct a European
multi-center study? But also, has the new Directive
achieved the goal of simplifying and harmonizing the
administrative provisions governing clinical trials in EU
countries?
As a University Medical Center, we have experienced
the practical consequences of the Clinical Trials Directive
at ﬁrst hand during a European multi-center study on
instrumented lumbar spinal fusions with the use of Osteo-
genic Protein-1 (OP-1). The objective of this paper is to
provide insight in the difﬁculties involved while conduct-
ing such a European multi-center study under the new EU
Clinical Trials Directive.
Background
The reason for implementation of the Clinical Trial Direc-
tive was that the rules and requirements concerning clinical
trials diverged considerably in the Member States, resulting
in delays and complications detrimental to the effective
conduct of European trials in the Community. It was
therefore necessary to simplify and harmonize the admin-
istrative provisions governing such trials by establishing a
clear, transparent procedure and creating conditions con-
ducive to effective coordination of such trials.
Most objections to this directive were based on the con-
ception that the Directive was conceived as a way of
facilitating commercial drug development and that publicly
funded trials were forced to fulﬁll the same requirements as
their commercial counterparts [2]. The new requirements
would impose a much greater administrative burden to
independent and academic clinical research. Several articles
addressed the essential role of independent research and
expressed concerns about the increasing inﬂuence of
industrial funding [1, 3, 9]. The research agenda can in this
way be dictated by commercial proﬁt only and thereby
neglect research considered economically uninteresting [9,
10, 12]. These are real concerns as the objectivity of
industry-driven trials have been frequently disputed [3, 5, 6,
11]. Out of concern for the future of academic research after
the implementation of the new Directive, the ‘‘Save Euro-
pean Research’’ campaign was started, calling on the
European Commission to repeal its Directive [8]. Despite
the lobbyingtowardsthepolicymakerstoappreciatethe role
of non-commercial research, the European Union decided
that the Directive must be incorporated into the national
legislation in each Member State before May 2004.
Sinceourinstitutionwasresponsiblefortheinitiationand
management of this aforementioned trial, we were,
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DOI 10.1007/s00586-008-0699-5according to the deﬁnition of the Directive, considered ‘the
sponsor’ of the trial. In this role we were one of the ﬁrst
academiccenterstobefacedwithdirectconsequencesofthe
new Directive in the perspective of a European multi-center
clinicaltrial.Theparticipantsofthisstudyinitiallyconsisted
of spinal surgeons of 12 hospitals located in Germany, the
Netherlands, Spain, France, United Kingdom and Italy.
During the course of this study we ran into a great deal of
anticipated as well as unanticipated difﬁculties.
Encountered problems
Although the EU Member States were required to have
implemented the Directive by May 2004, not all Member
States were able to transpose the Directive in their national
legislation by this date. As a consequence, we were obliged
to fulﬁll the new guidelines of the Directive for some of
participating centers, while for other centers their original
national requirements were still applicable. Due to this
dichotomy in requirements, the responsibilities and obli-
gations of our hospital, as the initiator and coordinator of
the study, were not completely clear, not even to the Ethic
Committees or Competent Authorities involved.
The Directive and implementing guidelines imposed
many administrative requirements that did not exist, or were
not similarly developed in the Member States [13]. This
included an obligatory new Database (EUDRACT), an
authorization requesttothe competent authorities,aswell as
anInvestigationalMedicinalProductDossier;annualreports
for clinical trials; adverse reaction reports and ﬁnal study
reports. The Clinical Trials Directive also introduced Good
Clinical Practice (GCP) principles to ensure that trials are
conducted in accordance with high standards of ethics and
science. Although the practice of GCP were standard in all
Member States, only a minority of Member States had pre-
viously codiﬁed the obligations of the different parties and
the involvement of the competent authorities as now
imposed by the Directive. GCP is a standard for the design,
conduct,monitoring,analyses,andreportingofclinicaltrials
that provides assurance that the data and reported results are
credible and accurate and that the rights of trial subjects are
protected. The requirements of GCP are noted in a 53 pages
containing manual describing practices, responsibilities and
actions of all members involved. One of the requirements of
GCP is that the sponsor establishes an independent data
monitoring committee. The monitoring committee needs to
assess atfrequent intervalstheprogressofaclinicaltrial,the
safety of data, and the critical efﬁcacy endpoints. During
these visits the reported trial data should be veriﬁable to the
monitor from source documents, i.e. patient ﬁles, surgery
reports,chartingnotes,nursingnotes.Eachparticipatingsite
needs to be visited numerous times, making this a large, and
time-consuming administrative activity, not only for the
monitor, but also for the physicians involved. Additionally,
monitoring is associated with high costs, especially when
multiple international sites are included in the clinical trial.
A major difﬁculty of conducting a European multi-center
study remains, despite the EU Clinical Trials Directive, that
each country, and sometimes even different hospitals within
the same country, requires separate approval of the study
protocolbythelocalauthorities.Thisimpliesthatsubmission
totheEthicsCommitteesandCompetentAuthoritiesneedsto
be repeated in each EU country for the same study. We have
applied for approval to conduct our study to the involved
authorities 14 times. On top of that, the procedures to obtain
this approval also differ greatly between different EU coun-
tries. The linguistic problems in the communication with the
local authorities of some of the countries, demanding corre-
spondence in their own local language, hampered
communication considerably. For instance, we were repeat-
edly asked to sign ofﬁcial documents and declarations,
sometimes even with an obvious legal status, in the local
language. Surprisingly, in most cases an English translation
wasnotaccepted,sinceincertaincountriesofﬁcialdocuments
will onlybeissuedintheirlocallanguage.Obviously,ofﬁcial
documents need to be in a mutually understandable language
and the sponsor cannot sign a contract in a language he does
not understand. Next to these linguistic problems, most ofﬁ-
cialdocumentsstillrefertoseveralnationallawsofwhichwe
did not know the exact content.
What practical consequences did the new Directive have
forourstudy?Twohospitalswereexcludedduetothedelays
and difﬁculties caused by the new requirements. The com-
pletion of the study was delayed for at least one year. The
delays were for a large extent due to the new administrative
proceduresoftheDirective.Also,additionalfundingneeded
to be obtained to cover the extra costs of the monitoring
requirements. Last, but certainly not least, the substantially
increased administrative burden has undoubtedly reduced
the enthusiasm and commitment of the physicians involved.
In some cases even to the extent that they declared not to
participate in these kind of studies again in the future.
The need for centralization
Were the concerns regarding the new EU Clinical Trials
Directive legitimate? The answer is clearly: yes. The
Directive has created many additional burdens for the
conduction of academic trials independent of medical
industry, while it did not meet the primary objective of
harmonizing and simplifying the legislation in the Member
States. It is now almost impossible for a group of physi-
cians to conduct a European multi-center study
independent of the industrial organizations and
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123infrastructures. Clearly, this dependence is not desirable
and it should be possible for surgeons and physicians to
conduct studies independently.
The goal of the Directive to harmonize the legislation
concerning clinical trials throughout the EU, was desirable,
not only to strengthen Europe’s economy by creating an
internal common market, but also for European non-com-
mercial research to be globally competitive. This legislation
should guarantee the rights, safety and well-being of trial
subjects, and insure that the results of the clinical trials are
credible and reliable. It is obvious that the ethical and sci-
entiﬁc quality should be veriﬁable to judgingauthorities and
thatthisdemandsprovisionofsufﬁcientinformationtothese
authorities. The information being requested, however,
should bear relation with its purpose. Under the new Direc-
tive, application forms have grown to the size of books,
carrying a message of general distrust of physicians, and it
overlooks the fact that it is also in the best interests of the
physicians to comply with demanded quality standards. The
currently increased administrative requirements are inver-
sely correlated to the physicians’ enthusiasm to conduct
independentclinicaltrials.Inordertoavoidthattheresearch
agenda in the future will be dictated by the medical industry
and to preserve the unique role of independent research, the
loadofthepaperworktophysicians,whileconductingsucha
study, should diminish signiﬁcantly.
Despite the new Directive, separate approval from each
national authority is still required before a clinical trial can
start. This, in combination with a lack of uniformity in the
procedures and communication in a mutually understand-
able langue, make conduction of clinical trials a needlessly
laborious and frustrating experience. It is a missed oppor-
tunity of the European Commission that they did not
promote centralization of approval procedures, meaning
that one central European authority to give approval for all
Member States involved. This should not only be a central
Ethics Committee that approves the trial for all European
countries, but a central organ that also provides the
authorization for all Competent Authorities involved. This
would have signiﬁcantly contributed in simplifying and
harmonizing the legislation regarding clinical trials.
We believe that the professional organizations of the
European physicians and surgeons should make efforts to
facilitate non-commercial studies and put pressure on
political authorities to reduce the administrative require-
ments concerning such trials. One important aspect in
achieving this, is the implementation of central authority
for application of trials, that applies in all Member States.
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